Clinical Trial Update: A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is investigating an osimertinib-based adaptive treatment guided by ctDNA EGFR mutation monitoring in locally advanced or metastatic EGF…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: Locally Advanced or Metastatic EGFRm Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: RECRUITING